CPT® Code 91314

Deleted

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use

The CPT® Code 91314 refers to a specific vaccine designed to provide immunity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for the disease known as coronavirus disease (COVID-19). This vaccine utilizes a bivalent formulation, meaning it contains messenger RNA (mRNA) components that correspond to both the original strain of the virus and a variant associated with the omicron lineage, specifically targeting the BA.4 and BA.5 subvariants. The vaccine is preservative-free and is administered in a dosage of 25 mcg per 0.25 mL via intramuscular injection. The mRNA is encapsulated in lipid nanoparticles (LNP), which facilitate the delivery of the genetic material into the body's cells. Once inside, the cells utilize the mRNA as a template to produce the spike protein found on the surface of the coronavirus. This process triggers an immune response, prompting the body to generate antibodies that can recognize and combat the virus if encountered in the future. The administration of this vaccine is particularly aimed at individuals aged 6 through 11 years who have previously received COVID-19 vaccinations, serving as a booster to enhance their immune protection against the virus. It is important to note that while this code reports the supply of the vaccine, the actual injection procedure is documented separately using the appropriate administration code.